Abstract

Plasminogen activator inhibitor-1 (PAI-1) is a typical member of the serpin family that kinetically traps its target proteinase as a covalent complex by distortion of the proteinase domain. Incorporation of the fluorescently silent 4-fluorotryptophan analog into PAI-1 permitted us to observe changes in the intrinsic tryptophan fluorescence of two-chain tissue-type plasminogen activator (tPA) and the proteinase domain of tPA during the inhibition reaction. We demonstrated three distinct conformational changes of the proteinase that occur during complex formation and distortion. A conformational change occurred during the initial formation of the non-covalent Michaelis complex followed by a large conformational change associated with the distortion of the proteinase catalytic domain that occurs concurrently with the formation of stable proteinase-inhibitor complexes. Following distortion, a very slow structural change occurs that may be involved in the stabilization or regulation of the trapped complex. Furthermore, by comparing the inhibition rates of two-chain tPA and the proteinase domain of tPA by PAI-1, we demonstrate that the accessory domains of tPA play a prominent role in the initial formation of the non-covalent Michaelis complex.

Highlights

  • Plasminogen activator inhibitor-1 (PAI-1)1 is the predominant physiologic inhibitor of both tissue-type plasminogen activator and urinary-type plasminogen activator and has been shown to play a diverse role in a variety of physiologic processes including coagulation, matrix remodeling, complement activation, tumor invasion, and angiogenesis [1]

  • To ensure that the changes in tryptophan fluorescence are solely attributed to conformational transitions within the proteinase, it is necessary to obviate tryptophan fluorescence changes within PAI-1 during the inhibition reaction

  • We have created a variant of PAI-1 in which all four tryptophan residues are biosynthetically replaced with the non-fluorescent 4-fluorotryptophan analog

Read more

Summary

Introduction

Plasminogen activator inhibitor-1 (PAI-1)1 is the predominant physiologic inhibitor of both tissue-type plasminogen activator (tPA) and urinary-type plasminogen activator and has been shown to play a diverse role in a variety of physiologic processes including coagulation, matrix remodeling, complement activation, tumor invasion, and angiogenesis [1]. Incorporation of the fluorescently silent 4-fluorotryptophan analog into PAI-1 permitted us to observe changes in the intrinsic tryptophan fluorescence of two-chain tissue-type plasminogen activator (tPA) and the proteinase domain of tPA during the inhibition reaction.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.